Hong Kong, China, 27 September 2023 — Recently, the 16th Asia Pacific Heart Rhythm Society Scientific Session (APHRS 2023) was held in Hong Kong. MicroPort EP and MicroPort® CRM actively participated in the exhibition and engaged experts in academic discussions.
The APHRS Annual Scientific Conference is an internationally renowned congress in the field of cardiac arrhythmia treatment. It covers a wide range of cutting-edge applications and focuses on unmet clinical needs and hot topics, making it highly influential in the industry.
MicroPort EP showcased innovative products in the field of electrophysiology intervention diagnosis and ablation treatment, including the Columbus™ 3D EP Navigation System V3 (the Columbus™ system), along with its accompanying FireMagic™ TrueForce™ Ablation Catheter, and other products in the comprehensive series. MicroPort® CRM showcased the ENO™ and ALIZEA™ pacemakers, along with the ULYS™ and GALI™ high voltage devices, as well as a full range of leads.
The booth attracted experts from countries such as the United States, Japan, Australia, Turkey, Kazakhstan, Argentina, Thailand, Vietnam, South Korea, and Indonesia, who visited to experience the performance of these solutions.
The regional nature of the congress presented us the opportunity to share experiences of our portfolio with and between clinicians and distributors across countries. MicroPort® is committed to providing more comprehensive solutions and professional services for patients and physicians worldwide.
Academic Conference and Demonstrations
During the exhibition, MicroPort EP participated in an academic conference titled "Novel Applications in Robotics, Remote Control, Automation and New 3D Mapping Integration in Catheter Ablation", which was jointly organized by APHRS and SCRN. Dr. Yiyong Sun, President of MicroPort EP, delivered a comprehensive presentation, outlining MicroPort EP’s 17-year development journey in the field of electrophysiology, electrophysiology product solutions, and the progress of collaborative research and development projects with Stereotaxis™. Currently, MicroPort EP has completed the development and integration of the Columbus™ RMN module, which enables remote control of the MagBot® Magnetic Catheter for the construction, mapping, and ablation of the 3D cardiac cavity model. These products are expected to receive market approval in China next year.
During the conference, Dr. Qi Jin, from the Cardiology Department of Ruijin Hospital in Shanghai, operated the Columbus™ system, MagBot® Magnetic Catheter, and Genesis™ system. He successfully demonstrated a series of functions to the experts in attendance at the on-site venue in Hong Kong via live streaming, including construction, mapping, and automated navigation. Dr. Qi Jin efficiently constructed the left atrial cavity model by manipulating the magnetic field direction arrows of the Columbus™ system. He marked the positions of pulmonary veins and the posterior wall and demonstrated the entire process of the catheter being automatically guided to the set target location by the system. Throughout the process, the catheter responded quickly without any noticeable delay. This was the first public demonstration of the magnetic navigation electrophysiology technology developed by MicroPort EP.
Furthermore, the conference featured multiple live surgeries conducted using magnetic navigation robots. Dr. Alexander Romanov remotely controlled a magnetic navigation device located in Russia to perform on-site pulmonary artery denervation during the conference. Surgical teams from Wuxi People's Hospital in China and Fuwai Central China Cardiovascular Hospital successfully performed remote robotic magnetic navigation catheter ablation for cardiac arrhythmia through a 5G network connection.
About MicroPort EP
Founded in Shanghai in 2010, Shanghai MicroPort EP MedTech Co., Ltd. (“MicroPort EP”, stock code: 688351.SH) is a global medical devices company focusing on the development, manufacturing, and marketing of minimally invasive medical devices for the treatment of cardiac arrhythmia disease. It has developed a family of advanced cardiac ablation catheters, diagnostic catheters, and 3D navigation systems. At MicroPort EP, we strive to provide integrated therapeutic solutions to apply precise navigation on interventional procedures, dedicated to providing high quality therapeutic solutions to patients and physicians across the globe.
More information is available at www.everpace.com.
About MicroPort® CRM
MicroPort® CRM is a pioneering company in the field of Cardiac Rhythm Management (CRM) with world headquarters in Clamart, near Paris, France. Through its long-standing expertise in CRM, MicroPort® CRM develops, manufactures and markets cardiac pacemakers, implantable cardiac defibrillators, cardiac resynchronization systems and ECG diagnostic solutions for the management of cardiac rhythm disorders and heart failure, globally.
More information is available at www.microport.com.